Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide

Conditioning with busulphan (BU) and cyclophosphamide (CY) prior to allogeneic bone marrow transplantation (BMT) is an alternative to regimens that include total body irradiation (TBI). The aim of the study was to assess the occurrence and degree of lung function impairment after this treatment. Pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal 1995-08, Vol.8 (8), p.1269-1274
Hauptverfasser: Lund, MB, Kongerud, J, Brinch, L, Evensen, SA, Boe, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1274
container_issue 8
container_start_page 1269
container_title The European respiratory journal
container_volume 8
creator Lund, MB
Kongerud, J
Brinch, L
Evensen, SA
Boe, J
description Conditioning with busulphan (BU) and cyclophosphamide (CY) prior to allogeneic bone marrow transplantation (BMT) is an alternative to regimens that include total body irradiation (TBI). The aim of the study was to assess the occurrence and degree of lung function impairment after this treatment. Prospectively, 43 consecutive patients, aged 17-51 (median 31) yrs, were examined by lung function measurements and clinical and radiographic evaluation, prior to BMT and at 3 month intervals up to 1 yr after BMT. All patients had normal chest radiographs before BMT and at the 12 month follow-up. Mean baseline values were above 100% of predicted normal for lung volumes and above 90% for gas transfer. Excluded from the lung function follow-up analyses were nine patients who had suffered infectious pneumonia and/or developed obliterative bronchiolitis. For the remaining patients (n = 34), mean alveolar volume (VA), forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) had dropped by nearly 10% compared with baseline 3 months after BMT, but were restored within 1 yr. FEV1/FVC x 100 (FEV1%) was increased, reflecting the restrictive pattern. Hb-adjusted transfer factor of the lungs for carbon monoxide (TL,CO) had dropped by 20% after 3 months, and remained reduced by 15% after 1 year. Prior to BMT the smokers had significantly lower TL,CO than the nonsmokers, and after BMT the difference was accentuated. Reductions in lung function were independent of sex, age and type of haematological disorder. We conclude that BMT with BU/CY is associated with transient declines in lung volumes and a persistent reduction in gas transfer 1 yr after therapy.
doi_str_mv 10.1183/09031936.95.08081269
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1183_09031936_95_08081269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>7489789</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3229-6fc5e87ddd4d84912ffabbe6b20b60399667fb5efb34b6c87749968f4ec462753</originalsourceid><addsrcrecordid>eNo9kM1uGyEURlHVKnXSvkErsWiX48DAMLCskjSpZCmbdo349RCNYQSeWH6MvHGZ2MkKdO_5PsQB4BtGa4w5uUYCESwIW4tujTjiuGXiA1hhIkRDECIfwWpBmoX5DC5LeUIIM0rwBbjoKRc9FyvwcutMdqo4C8c5bqGfo9mHFGGIMEUHj05lWOb8HJ5TLjB5qMYxbV10wUC9EDuVczrAfVaxTKOKe_WaNynasNxq8yHsBziE7dDYVBzUc5nHaVARqmihOZoxTUMqdbIL1n0Bn7wai_t6Pq_Av993f28ems3j_Z-bX5vGkLYVDfOmc7y31lLLqcCt90prx3SLNEPVAWO9153zmlDNDO97WmfcU2coa_uOXAF66jU5lZKdl1MO9TNHiZFcBMs3wVJ08k1wjX0_xaZZ75x9D52N1v2P814Vo0ZftZhQ3jHCOoQoq9jPE7ZoOYTsZNlVs7UUS5efuOTy9bn_bJ-UPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lund, MB ; Kongerud, J ; Brinch, L ; Evensen, SA ; Boe, J</creator><creatorcontrib>Lund, MB ; Kongerud, J ; Brinch, L ; Evensen, SA ; Boe, J</creatorcontrib><description>Conditioning with busulphan (BU) and cyclophosphamide (CY) prior to allogeneic bone marrow transplantation (BMT) is an alternative to regimens that include total body irradiation (TBI). The aim of the study was to assess the occurrence and degree of lung function impairment after this treatment. Prospectively, 43 consecutive patients, aged 17-51 (median 31) yrs, were examined by lung function measurements and clinical and radiographic evaluation, prior to BMT and at 3 month intervals up to 1 yr after BMT. All patients had normal chest radiographs before BMT and at the 12 month follow-up. Mean baseline values were above 100% of predicted normal for lung volumes and above 90% for gas transfer. Excluded from the lung function follow-up analyses were nine patients who had suffered infectious pneumonia and/or developed obliterative bronchiolitis. For the remaining patients (n = 34), mean alveolar volume (VA), forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) had dropped by nearly 10% compared with baseline 3 months after BMT, but were restored within 1 yr. FEV1/FVC x 100 (FEV1%) was increased, reflecting the restrictive pattern. Hb-adjusted transfer factor of the lungs for carbon monoxide (TL,CO) had dropped by 20% after 3 months, and remained reduced by 15% after 1 year. Prior to BMT the smokers had significantly lower TL,CO than the nonsmokers, and after BMT the difference was accentuated. Reductions in lung function were independent of sex, age and type of haematological disorder. We conclude that BMT with BU/CY is associated with transient declines in lung volumes and a persistent reduction in gas transfer 1 yr after therapy.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/09031936.95.08081269</identifier><identifier>PMID: 7489789</identifier><language>eng</language><publisher>Leeds: Eur Respiratory Soc</publisher><subject>Adolescent ; Adult ; Antineoplastic agents ; Biological and medical sciences ; Bone Marrow Transplantation - adverse effects ; Busulfan - administration &amp; dosage ; Busulfan - adverse effects ; Chemotherapy ; Cyclophosphamide - administration &amp; dosage ; Cyclophosphamide - adverse effects ; Female ; Forced Expiratory Volume ; Hemoglobins - analysis ; Humans ; Immunosuppressive Agents - administration &amp; dosage ; Immunosuppressive Agents - adverse effects ; Lung Diseases - etiology ; Lung Volume Measurements ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prospective Studies ; Pulmonary Diffusing Capacity ; Respiratory Mechanics - drug effects</subject><ispartof>The European respiratory journal, 1995-08, Vol.8 (8), p.1269-1274</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3229-6fc5e87ddd4d84912ffabbe6b20b60399667fb5efb34b6c87749968f4ec462753</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3650046$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7489789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lund, MB</creatorcontrib><creatorcontrib>Kongerud, J</creatorcontrib><creatorcontrib>Brinch, L</creatorcontrib><creatorcontrib>Evensen, SA</creatorcontrib><creatorcontrib>Boe, J</creatorcontrib><title>Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>Conditioning with busulphan (BU) and cyclophosphamide (CY) prior to allogeneic bone marrow transplantation (BMT) is an alternative to regimens that include total body irradiation (TBI). The aim of the study was to assess the occurrence and degree of lung function impairment after this treatment. Prospectively, 43 consecutive patients, aged 17-51 (median 31) yrs, were examined by lung function measurements and clinical and radiographic evaluation, prior to BMT and at 3 month intervals up to 1 yr after BMT. All patients had normal chest radiographs before BMT and at the 12 month follow-up. Mean baseline values were above 100% of predicted normal for lung volumes and above 90% for gas transfer. Excluded from the lung function follow-up analyses were nine patients who had suffered infectious pneumonia and/or developed obliterative bronchiolitis. For the remaining patients (n = 34), mean alveolar volume (VA), forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) had dropped by nearly 10% compared with baseline 3 months after BMT, but were restored within 1 yr. FEV1/FVC x 100 (FEV1%) was increased, reflecting the restrictive pattern. Hb-adjusted transfer factor of the lungs for carbon monoxide (TL,CO) had dropped by 20% after 3 months, and remained reduced by 15% after 1 year. Prior to BMT the smokers had significantly lower TL,CO than the nonsmokers, and after BMT the difference was accentuated. Reductions in lung function were independent of sex, age and type of haematological disorder. We conclude that BMT with BU/CY is associated with transient declines in lung volumes and a persistent reduction in gas transfer 1 yr after therapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation - adverse effects</subject><subject>Busulfan - administration &amp; dosage</subject><subject>Busulfan - adverse effects</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide - administration &amp; dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Female</subject><subject>Forced Expiratory Volume</subject><subject>Hemoglobins - analysis</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration &amp; dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Lung Diseases - etiology</subject><subject>Lung Volume Measurements</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Pulmonary Diffusing Capacity</subject><subject>Respiratory Mechanics - drug effects</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1uGyEURlHVKnXSvkErsWiX48DAMLCskjSpZCmbdo349RCNYQSeWH6MvHGZ2MkKdO_5PsQB4BtGa4w5uUYCESwIW4tujTjiuGXiA1hhIkRDECIfwWpBmoX5DC5LeUIIM0rwBbjoKRc9FyvwcutMdqo4C8c5bqGfo9mHFGGIMEUHj05lWOb8HJ5TLjB5qMYxbV10wUC9EDuVczrAfVaxTKOKe_WaNynasNxq8yHsBziE7dDYVBzUc5nHaVARqmihOZoxTUMqdbIL1n0Bn7wai_t6Pq_Av993f28ems3j_Z-bX5vGkLYVDfOmc7y31lLLqcCt90prx3SLNEPVAWO9153zmlDNDO97WmfcU2coa_uOXAF66jU5lZKdl1MO9TNHiZFcBMs3wVJ08k1wjX0_xaZZ75x9D52N1v2P814Vo0ZftZhQ3jHCOoQoq9jPE7ZoOYTsZNlVs7UUS5efuOTy9bn_bJ-UPg</recordid><startdate>199508</startdate><enddate>199508</enddate><creator>Lund, MB</creator><creator>Kongerud, J</creator><creator>Brinch, L</creator><creator>Evensen, SA</creator><creator>Boe, J</creator><general>Eur Respiratory Soc</general><general>Maney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199508</creationdate><title>Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide</title><author>Lund, MB ; Kongerud, J ; Brinch, L ; Evensen, SA ; Boe, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3229-6fc5e87ddd4d84912ffabbe6b20b60399667fb5efb34b6c87749968f4ec462753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation - adverse effects</topic><topic>Busulfan - administration &amp; dosage</topic><topic>Busulfan - adverse effects</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide - administration &amp; dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Female</topic><topic>Forced Expiratory Volume</topic><topic>Hemoglobins - analysis</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration &amp; dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Lung Diseases - etiology</topic><topic>Lung Volume Measurements</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Pulmonary Diffusing Capacity</topic><topic>Respiratory Mechanics - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lund, MB</creatorcontrib><creatorcontrib>Kongerud, J</creatorcontrib><creatorcontrib>Brinch, L</creatorcontrib><creatorcontrib>Evensen, SA</creatorcontrib><creatorcontrib>Boe, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lund, MB</au><au>Kongerud, J</au><au>Brinch, L</au><au>Evensen, SA</au><au>Boe, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>1995-08</date><risdate>1995</risdate><volume>8</volume><issue>8</issue><spage>1269</spage><epage>1274</epage><pages>1269-1274</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>Conditioning with busulphan (BU) and cyclophosphamide (CY) prior to allogeneic bone marrow transplantation (BMT) is an alternative to regimens that include total body irradiation (TBI). The aim of the study was to assess the occurrence and degree of lung function impairment after this treatment. Prospectively, 43 consecutive patients, aged 17-51 (median 31) yrs, were examined by lung function measurements and clinical and radiographic evaluation, prior to BMT and at 3 month intervals up to 1 yr after BMT. All patients had normal chest radiographs before BMT and at the 12 month follow-up. Mean baseline values were above 100% of predicted normal for lung volumes and above 90% for gas transfer. Excluded from the lung function follow-up analyses were nine patients who had suffered infectious pneumonia and/or developed obliterative bronchiolitis. For the remaining patients (n = 34), mean alveolar volume (VA), forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) had dropped by nearly 10% compared with baseline 3 months after BMT, but were restored within 1 yr. FEV1/FVC x 100 (FEV1%) was increased, reflecting the restrictive pattern. Hb-adjusted transfer factor of the lungs for carbon monoxide (TL,CO) had dropped by 20% after 3 months, and remained reduced by 15% after 1 year. Prior to BMT the smokers had significantly lower TL,CO than the nonsmokers, and after BMT the difference was accentuated. Reductions in lung function were independent of sex, age and type of haematological disorder. We conclude that BMT with BU/CY is associated with transient declines in lung volumes and a persistent reduction in gas transfer 1 yr after therapy.</abstract><cop>Leeds</cop><pub>Eur Respiratory Soc</pub><pmid>7489789</pmid><doi>10.1183/09031936.95.08081269</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0903-1936
ispartof The European respiratory journal, 1995-08, Vol.8 (8), p.1269-1274
issn 0903-1936
1399-3003
language eng
recordid cdi_crossref_primary_10_1183_09031936_95_08081269
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adolescent
Adult
Antineoplastic agents
Biological and medical sciences
Bone Marrow Transplantation - adverse effects
Busulfan - administration & dosage
Busulfan - adverse effects
Chemotherapy
Cyclophosphamide - administration & dosage
Cyclophosphamide - adverse effects
Female
Forced Expiratory Volume
Hemoglobins - analysis
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
Lung Diseases - etiology
Lung Volume Measurements
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Prospective Studies
Pulmonary Diffusing Capacity
Respiratory Mechanics - drug effects
title Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T12%3A57%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decreased%20lung%20function%20in%20one%20year%20survivors%20of%20allogeneic%20bone%20marrow%20transplantation%20conditioned%20with%20high-dose%20busulphan%20and%20cyclophosphamide&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Lund,%20MB&rft.date=1995-08&rft.volume=8&rft.issue=8&rft.spage=1269&rft.epage=1274&rft.pages=1269-1274&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/09031936.95.08081269&rft_dat=%3Cpubmed_cross%3E7489789%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7489789&rfr_iscdi=true